Join us for a pitch feedback session open to all startups exhibiting at TC Sessions: Space 2020 moderated by TechCrunch staff.
Join us for a pitch feedback session open to all startups exhibiting at TC Sessions: Space 2020 moderated by TechCrunch staff.
The European charter for robots and humans working together has been officially released by the European Engineering Industries Association (EUnited). The document defines 10 focus areas to shape the future of work. The charter supports the UNITED NATIONS Sustainable Development Goals (SDGs) for 2030.
According to the [190+ Pages] research report; the global Ophthalmic Drug Market in 2019 was approximately USD 27,000 Million. The market is expected to grow at a CAGR of 4.6% and is anticipated to reach around USD 37,700 Million by 2026. Top market players are Santen Pharmaceutical Co. Ltd., Bayer AG, ALLERGAN, Novartis AG, Pfizer Inc., Genentech Inc. and others.New York, NY, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “Ophthalmic Drug Market By Type (Over-the-Counter Drugs and Prescription Drugs), By Drug Class (Anti-inflammatory Drugs, Anti-Infective Drugs, Anti-Allergic Drugs, Anti-Glaucoma Drugs, and Others), By Disease Indication (Inflammation/ Infection, Retinal Disorders, Dry Eye, Glaucoma, Allergies, and Others), By Distribution Channel (Online Sales, Retail Pharmacies, Hospital Pharmacies, and Others), and By Region: Global Industry Perspective, Market Size, Statistical Research, Market Intelligence, Comprehensive Analysis, Historical Trends, and Forecasts, 2019–2026”. “According to the research study, the global Ophthalmic Drug Market was estimated at USD 27,000 Million in 2019 and is expected to reach USD 37,700 Million by 2026. The global Ophthalmic Drug Market is expected to grow at a compound annual growth rate (CAGR) of 4.6% from 2019 to 2027”. Ophthalmic drugs, also referred to as eye medications, are solid, liquid, or semi-solid formulations that are intended to apply on the eyelids and conjunctiva. The drugs are certain emulsions, ointments, and/or active pharmaceutical ingredient(s). Request Your Free Sample Report of Ophthalmic Drug Market @ https://www.fnfresearch.com/sample/global-ophthalmic-drug-market-global-ophthalmic-drugmarket-by (The free sample of this report is readily available on request). Our Free Sample Report Includes: 2020 Updated Report Introduction, Overview, and In-depth industry analysisCOVID-19 Pandemic Outbreak Impact Analysis Included190+ Pages Research Report (Inclusion of Updated Research)Provide Chapter-wise guidance on Request2020 Updated Regional Analysis with Graphical Representation of Size, Share & TrendsIncludes Updated List of table & figuresUpdated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue AnalysisFacts and Factors research methodology (Note: The sample of this report is updated with COVID-19 impact analysis before delivery) Key Questions Answered in this Report 1) What was the impact of COVID-19 on the Ophthalmic Drug Market? 2) What is the market size, share of the Ophthalmic Drug Market? 3) Who are the top market players in Ophthalmic Drug Market? 4) What will be the future market of the Ophthalmic Drug Market? Key Offerings: Market Size & Forecast by Revenue | 2020−2026Market Dynamics – Leading trends, growth drivers, restraints, and investment opportunitiesMarket Segmentation – A detailed analysis by product, by types, end-user, applications, segments, and geographyCompetitive Landscape – Top key vendors and other prominent vendors Inquire more about this report before purchase @ https://www.fnfresearch.com/inquiry/global-ophthalmic-drug-market-global-ophthalmic-drugmarket-by (You may enquire a report quote OR available discount offers to our sales team before purchase.) High prevalence of ocular disease cases likely to bolster the ophthalmic drug market The visual impairment incidences have been surging considerably worldwide irrespective of the age group. This challenging situation has urged drug manufacturers and pharmaceutical companies to design and supply effective medications against this rapidly spreading disorder. Hence, the introduction of novel effective ophthalmic drugs bolsters the global ophthalmic drug market. Exposure to air and water pollution poses a greater risk to the eyes. Thus, surging the demand for the drugs and propelling the global ophthalmic drug market. Key market players Some of the key players driving the global ophthalmic drugs market are Santen Pharmaceutical Co. Ltd., Bayer AG, ALLERGAN, Novartis AG, Pfizer Inc., Genentech Inc., Oxurion NV, Bausch Health Companies Inc., and Regeneron Pharmaceuticals Inc., among others. In February 2019, Bausch Health Companies Inc. procures the patent medicine EM-100 investigational eye drop designed by Eton Pharmaceuticals EM-100 for the treatment of itching associated with the allergies in eyes. To know an additional revised 2020 list of market players, request a sample report: https://www.fnfresearch.com/sample/global-ophthalmic-drug-market-global-ophthalmic-drugmarket-by Ophthalmic drugs-associated side effects expected to hamper the ophthalmic market Eye treatment involves a risky operation and has various side effects. In some cases, ophthalmic drugs fail to maintain the intraocular pressure of the eye while treatment. In most cases, the medicine may cause internal burning in the eye and/or temporary blurred vision. Owing to these attributes, the ophthalmic drugs market enters the declining phase. Anti-infective drug class leads the global ophthalmic drug market The anti-infective drug category, from the past few years, has been holding the dominating position in the global ophthalmic market. In 2019, the category accounts for more than one-third of the market share in terms of revenue. However, the anti-glaucoma drugs are projected to augment at a relatively faster CAGR throughout the forecast period. Directly Purchase a copy of the report with TOC @ https://www.fnfresearch.com/buynow/su/global-ophthalmic-drug-market-global-ophthalmic-drugmarket-by Over-the-counter drug type accounts for higher sales and revenue share Based on the type segment, ophthalmic drugs are categorized into prescription drugs and over-the-counter drugs. Among both, over-the-counter drug type holds around two-third share in the overall sales and revenue. However, the prescription drug category is anticipated to grow at a higher CAGR between 2020 and 2026. Retail pharmacies expect better sales and revenue share during the forecast period Despite the consecutive decline in the volume sales, the revenue generated by retail pharmacies is thrusting at a considerable rate. Based on the forecast, the drug category is likely to follow the same revenue growth trend. However, the hospital pharmacies category holds the leading position in the global market revenue generation. Request Customized Copy of Report @ https://www.fnfresearch.com/customization/global-ophthalmic-drug-market-global-ophthalmic-drugmarket-by (We customize your report according to your research need. Ask our sales team for report customization.) The visual impairment incidences have been surging considerably worldwide irrespective of the age group. This challenging situation has urged drug manufacturers and pharmaceutical companies to design and supply effective medications against this rapidly spreading disorder. Hence, the introduction of novel effective ophthalmic drug bolsters the global ophthalmic drug market. Exposure to air and water pollution poses a greater risk to the eyes. Thus, surging the demand for the drugs and propelling the global ophthalmic drug market. The global ophthalmic drug market is segmented based on type, drug class, disease indication, distribution channel, and region. By type, the market is segmented into over-the-counter drugs and prescription drugs. Drug class classifies the market into anti-inflammatory drugs, anti-infective drugs, anti-allergic drugs, anti-glaucoma drugs, and others. Based on disease indication, the global market is categorized into inflammation/ infection, retinal disorders, dry eye, glaucoma, allergies, and others. The distribution channel segment of the global magnesium chloride market is sectored into online sales, retail pharmacies, hospital pharmacies, and others. Browse the full “Ophthalmic Drug Market By Type (Over-the-Counter Drugs and Prescription Drugs), By Drug Class (Anti-inflammatory Drugs, Anti-Infective Drugs, Anti-Allergic Drugs, Anti-Glaucoma Drugs, and Others), By Disease Indication (Inflammation/ Infection, Retinal Disorders, Dry Eye, Glaucoma, Allergies, and Others), By Distribution Channel (Online Sales, Retail Pharmacies, Hospital Pharmacies, and Others), and By Region: Global Industry Perspective, Market Size, Statistical Research, Market Intelligence, Comprehensive Analysis, Historical Trends, and Forecasts, 2019–2026" report at https://www.fnfresearch.com/global-ophthalmic-drug-market-global-ophthalmic-drugmarket-by The global ophthalmic drugs market is segmented as: Global Ophthalmic Drugs Market: Type Segmentation Analysis Over-the-Counter DrugsPrescription Drugs Global Ophthalmic Drugs Market: Drug Class Segmentation Analysis Anti-Infective Drugs Anti-Bacterial DrugsAnti-Fungal DrugsAnti-Viral DrugsOthers Anti-Glaucoma Drugs Prostaglandin AnalogsAlpha AgonistBetaBlockersCombined MedicationOthers Anti-inflammatory Drugs SteroidsNon-Steroidal Anti-Inflammatory Drugs Anti-Allergic DrugsOthers Global Ophthalmic Drugs Market: Disease Indication Segmentation Analysis Inflammation/ InfectionRetinal DisordersDry EyeGlaucomaAllergiesOthers Global Ophthalmic Drugs Market: Distribution Channel Segmentation Analysis Online SalesRetail PharmaciesHospital PharmaciesOthers Key Recommendations from Analysts Based on the analytical data, the global ophthalmic market generated a revenue of over USD 27,000 million in 2019 and is projected to reach a value close to USD 37,700 million propelling at a rate of around 4.6%.According to analysts, the cases of ophthalmic disorders are rising considerably due to the increasing environmental pollution, especially air & water, which in turn flourishes the global ophthalmic drug market.Analysts indicated that North America dominated the global ophthalmic market holding over 40% market share in terms of revenue and volume.The drugs associated with the “retinal disorders” category under the disease indication segment accounts for around one-third of the global ophthalmic market share.Hospital pharmacies generate considerably higher revenue through ophthalmic drug sales. However, analysts have indicated that the retail pharmacies category is anticipated to grow at a faster rate. Related Reports: Skin Antiseptic Products Market: https://www.fnfresearch.com/skin-antiseptic-products-market-by-type-solutions-swab 4D Printing in Healthcare Market: https://www.fnfresearch.com/4d-printing-in-healthcare-market-by-component-equipment Capsule Endoscopy Market: https://www.fnfresearch.com/global-capsule-endoscopy-market-by-product-capsule-endoscopes-588 Resuscitation Devices Market: https://www.fnfresearch.com/global-resuscitation-devices-market-by-product-airway-management-671 Needle Destroyer Market: https://www.fnfresearch.com/needle-destroyer-market-by-product-electrical-needle-burner-704 About Facts & Factors (FnF Research): Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business. Follow Us LinkedIn: https://www.linkedin.com/company/fnfresearch Follow Us Twitter: https://twitter.com/fnfresearch Contact Us: Facts & Factors USA: +1-347-989-3985 Email: firstname.lastname@example.org Web: https://www.fnfresearch.com Blog: http://fnfnewsblog.com
Pfizer will continue to supply its COVID-19 vaccine to Italy, respecting its agreement with the European Commission, even if Rome sues the company, the chief executive of the group's Italian unit said on Thursday. "We do not intend to speculate on this, but we will continue to supply the vaccine as envisaged by the agreements with the European Commission," the CEO of Pfizer in Italy, Paivi Kerkola, said in an interview with daily la Repubblica. Kerkola said that the group's supply of vaccine to Italy would be back to "regular" this week.
IOC President Thomas Bach has hit back at critics over doubts holding the Olympic Games in Tokyo is 'irresponsible'.
Everything you need to know
The transfer deadline is looming and we finally got one of the biggest deals of the window so far confirmed yesterday as Martin Odegaard joined Arsenal on loan from Real Madrid for the remainder of the season. The Gunners have been among the busiest of the Premier League clubs, mainly in the outgoings department, as Sokratis, Mesut Ozil and Sead Kolasniac have all departed, while goalkeeper Mat Ryan arrived from Brighton. Manchester United signed Amad Diallo from Atalanta early in the window but all the talk today is about in-form midfielder Paul Pogba, who says he will hold talks over his future at the end of the season.
Everything you need to know
Everything you need to know
(Bloomberg) -- Toyota Motor Corp. overtook Volkswagen AG in 2020 to become the world’s top-selling automaker, the first time the Japanese group has clinched the position in five years.Toyota’s group sales, which include those of its subsidiaries Daihatsu Motor Co. and Hino Motors Ltd., for the year were 9.53 million units, the company said Thursday. That compares with VW’s 9.31 million, announced earlier this month.The victory for Toyota came despite a painful year for automakers. Although demand for cars recovered marginally toward the end of 2020, industry-wide factory and showroom shutdowns in the spring were enough to drag sales down 14% from 2019, according to an estimate from IHS Markit.It was also a topsy-turvy year in which the gravity of automakers’ losses was largely determined by their level of exposure to the regions most disrupted by the virus.VW has a strong footprint in the European Union, where passenger car sales fell an “unprecedented” 24% to fewer than 10 million units in 2020, according to the European Automobile Manufacturers Association. The German carmaker’s sales fell 15%, its worst performance in close to a decade.VW Chief Executive Officer Herbert Diess initiated a strategic shift after he took over the top job in 2018 to focus on lifting profitability rather than chasing sales growth. VW’s return on sales has been lagging behind Toyota for years and the market slump triggered by the Covid-19 pandemic a year ago exposed the German manufacturer’s relatively high costs.Toyota, on the other hand, has a bigger presence in the U.S., where total car sales in the nation fell 15% in 2020. The Japanese automaker’s global sales were down 11%. Although the U.S. has the most Covid deaths and cases, there haven’t been the same lockdowns as in Europe.“Naturally the number of units sold was lower than in the previous year because of the spread of coronavirus,” Toyota spokeswoman Chisato Yoshifuji said Thursday. “But because Toyota and its partners were able to thoroughly implement measures to combat the spread of the virus, we were able to continue our corporate activities and keep yearly declines at the level they were,” she said.Prior to 2020, VW outsold Toyota in every year since 2015. But the two companies’ results last year may be indicative of a longer-term trend, according to analysts.While VW is expected to temporarily surpass Toyota again in 2021, Toyota is projected to pull ahead each year through 2025, IHS Markit said. VW’s push to produce more electrified vehicles should lead to a sales spike this year, but prolonged lockdowns and shop closures in its domestic market will continue to have an adverse impact, analyst Yoshiaki Kawano said.Kawano said Toyota will continue to enjoy strong sales in its core markets of Japan and the U.S. In China, the world’s largest car market, it should “put up a good fight” by pushing out more EVs and SUVs in line with local demand, he said.Although a number of factors such as the continued spread of the virus and a global chip shortage will persist in 2021, IHS Markit estimates auto sales will recover steadily to 84.4 million units from 76.8 million in 2020. Global car sales are expected to touch 94.8 million in 2025.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The mum criticised Aldi for being 'arrogant' and while she claims to be a lawyer she might be the one in the wrong here.
(Bloomberg) -- Turkey’s central bank chief will unveil his inflation projections on Thursday, giving him a chance to ease fears that he will prematurely relax rates like his predecessors.Even as inflationary pressures mount, economists say Governor Naci Agbal may stick with his 2021 inflation forecast of 9.4% after declaring it an “interim target” that must be reached.“Higher commodity prices and minimum wages warrant an upward revision for end-2021 inflation forecast,” said Hakan Kara, a former chief economist at the central bank. “If the central bank does not change the forecast, this would signal a tighter monetary stance, in line with the recent hawkish monetary policy committee communication.”JPMorgan Chase & Co.analyst Yarkin Cebeci said he doesn’t expect a significant revision of the outlook. “Although my forecast is 10.5%, I see a decent chance that inflation falls to single digits at the end of the year,” he said.At the end of December, inflation was running almost triple the official 5% target.Last week, the central bank left its benchmark interest rate at 17% at the first monetary policy meeting of the year, pledging to keep it elevated for an “extended” period and deliver additional tightening if needed. The pause followed a cumulative increase of 675 basis points since Agbal took over, bringing inflation-adjusted borrowing costs well above yields offered by emerging-market peers.In December, the governor said the central bank’s year-end inflation estimate of 9.4%, set by his predecessor, is “an interim target that must be followed and reached.” The Monetary Policy Committee is next scheduled to discuss borrowing costs on Feb. 18.(Updates projections table with footnote.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Liverpool could be boosted by the return of Jordan Henderson for tonight’s clash with Tottenham after the skipper returned to training this week. Henderson, and Joel Matip, missed Sunday's FA Cup defeat to Manchester United, but their possible return will boost Jurgen Klopp's defensive options for the challenge of facing Harry Kane and Heung-min Son. "Hendo and Joel trained yesterday with the team fully," Klopp said.
AAPL earnings call for the period ending December 31, 2020.
There is a bit of mystery around Tottenham’s meeting with Liverpool tonight after Jose Mourinho hinted at some injury problems in the Spurs camp - but declined to say which players were struggling to be fit. Meanwhile, Standard Sport understands that Sergio Reguilon will miss the game - and is expected to be out for the next three weeks - due to a muscle problem. If Davies is not fit, then Japhet Tanganga may be drafted in at left-back.
CARGOTEC CORPORATION, PRESS RELEASE, 28 JANUARY 2021 AT 9:00 AM Cargotec closed the syndication of the merger financing arrangement Cargotec has closed the syndication regarding an EUR 300 million Term Loan Facility. The syndication was launched on the 30th November 2020 and the commitments received from the banks in the syndication led to significant oversubscription. Nordea Bank Abp managed the syndication process as Mandated Lead Arranger, Bookrunner and Exclusive Underwriter of the Facility. BNP Paribas, Danske Bank, OP Corporate Bank plc and SEB joined the facility as Mandated Lead Arrangers. Citi, Commerzbank Aktiengesellschaft, Crédit Agricole Corporate and Investment Bank, DBS Bank Ltd., London Branch, Deutsche Bank AG, Handelsbanken, Helaba, ING Belgium S.A./N.V., Santander, Standard Chartered and Swedbank AB (publ) were acting as Lead Arrangers. For further information, please contact:Mikko Puolakka, Executive Vice President and CFO, tel. +358 20 777 4105Hanna-Maria Heikkinen, Vice President, Investor Relations, tel. +358 20 777 4084 Cargotec (Nasdaq Helsinki: CGCBV) enables smarter cargo flow for a better everyday with its leading cargo handling solutions and services. Cargotec's business areas Kalmar, Hiab and MacGregor are pioneers in their fields. Through their unique position in ports, at sea and on roads, they optimise global cargo flows and create sustainable customer value. Cargotec's sales in 2019 totalled approximately EUR 3.7 billion and it employs around 12,000 people. www.cargotec.com
Cross-Border Commerce Europe - the platform that drives cross-border eCommerce in Europe - is launching a study that maps the 100 best global marketplaces in the sector and analyses their cross-border sustainability performance in Europe. eBay takes the pole position with a score of 68.9 out of 100. A study carried out by CBCommerce with support from FedEx Express and Worldline.
Akur8 partners with AXA Direct Japan to transform their insurance pricing process
Maistering, today announced a strategic 5-year digital partnership with Mesterbakeren.
Data on UDX's test could detect lung cancer sub-types early and indicate the potential of using blood-based screening for wider population
This announcement is an advertisement relating to the intention of the Company (as defined below) to proceed with the listing and admission of shares in Technip Energies (the "Shares") on Euronext Paris (the "Listing"). If and when the Listing is launched, further details about the Listing will be included in a prospectus to be published by the Company in relation to the Listing (the "Prospectus"). Once the Prospectus has been approved by the Netherlands Authority for the Financial Markets (Stichting Autoriteit Financiële Markten) (the "AFM") and passported to the Autorité des marchés financiers, the Prospectus will be published and made available at no cost through the corporate website of the Company (www.technipenergies.com).